Published in J Mol Biol on March 05, 1985
Structural basis for cAMP-mediated allosteric control of the catabolite activator protein. Proc Natl Acad Sci U S A (2009) 2.39
Cooperative DNA binding of heterologous proteins: evidence for contact between the cyclic AMP receptor protein and RNA polymerase. Proc Natl Acad Sci U S A (1988) 1.94
Mutants of the catabolite activator protein of Escherichia coli that are specifically deficient in the gene-activation function. Proc Natl Acad Sci U S A (1987) 1.81
Role of glutamic acid-181 in DNA-sequence recognition by the catabolite gene activator protein (CAP) of Escherichia coli: altered DNA-sequence-recognition properties of [Val181]CAP and [Leu181]CAP. Proc Natl Acad Sci U S A (1987) 1.75
Cyclic AMP-induced conformational change of cyclic AMP receptor protein (CRP): intragenic suppressors of cyclic AMP-independent CRP mutations. J Bacteriol (1988) 1.37
Functional similarities between the Listeria monocytogenes virulence regulator PrfA and cyclic AMP receptor protein: the PrfA* (Gly145Ser) mutation increases binding affinity for target DNA. J Bacteriol (1998) 1.27
Conversion of a helix-turn-helix motif sequence-specific DNA binding protein into a site-specific DNA cleavage agent. Proc Natl Acad Sci U S A (1990) 1.26
Modulation of the stability of a gene-regulatory protein dimer by DNA and cAMP. Proc Natl Acad Sci U S A (1989) 1.13
Pivotal role of amino acid at position 138 in the allosteric hinge reorientation of cAMP receptor protein. Proc Natl Acad Sci U S A (1993) 1.13
Mutations in the cyclic AMP binding site of the cyclic AMP receptor protein of Escherichia coli. Biochem J (1988) 1.12
Mutagenesis of the cyclic AMP receptor protein of Escherichia coli: targeting positions 83, 127 and 128 of the cyclic nucleotide binding pocket. Nucleic Acids Res (1994) 1.09
Escherichia coli cyclic AMP receptor protein mutants provide evidence for ligand contacts important in activation. J Bacteriol (1992) 1.03
Two-state allosteric modeling suggests protein equilibrium as an integral component for cyclic AMP (cAMP) specificity in the cAMP receptor protein of Escherichia coli. J Bacteriol (2008) 1.02
The Pseudomonas aeruginosa Vfr regulator controls global virulence factor expression through cyclic AMP-dependent and -independent mechanisms. J Bacteriol (2010) 1.01
Structural insights into the mechanism of the allosteric transitions of Mycobacterium tuberculosis cAMP receptor protein. J Biol Chem (2009) 0.95
Mutagenesis of the cyclic AMP receptor protein of Escherichia coli: targeting positions 72 and 82 of the cyclic nucleotide binding pocket. Nucleic Acids Res (1993) 0.95
Characterization of the CRPCY core formed after treatment with carboxypeptidase Y. Nucleic Acids Res (1991) 0.87
Characterization of the binding of cAMP and cGMP to the CRP*598 mutant of the E. coli cAMP receptor protein. Nucleic Acids Res (1990) 0.86
Mapping cyclic nucleotide-induced conformational changes in cyclicAMP receptor protein by a protein footprinting technique using different chemical proteases. Protein Sci (1999) 0.80
Crystallization and preliminary X-ray analysis of the ligand-binding domain of cAMP receptor protein. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.78
Directed Evolution of the Escherichia coli cAMP Receptor Protein at the cAMP Pocket. J Biol Chem (2015) 0.77
A highly specific cell-based high-throughput screening assay for ligands of cyclic adenosine monophosphate receptor protein in gram-negative bacteria. Assay Drug Dev Technol (2013) 0.75
Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol (1987) 9.10
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Transcription activation by catabolite activator protein (CAP). J Mol Biol (1999) 6.08
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) (1987) 5.01
Cancer linked to Alzheimer disease but not vascular dementia. Neurology (2009) 4.83
Promoter structure, promoter recognition, and transcription activation in prokaryotes. Cell (1994) 4.10
Aromatic hydrogen bond in sequence-specific protein DNA recognition. Nat Struct Biol (1996) 3.91
Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc Natl Acad Sci U S A (1998) 3.72
The AD8: a brief informant interview to detect dementia. Neurology (2005) 3.65
New core promoter element in RNA polymerase II-dependent transcription: sequence-specific DNA binding by transcription factor IIB. Genes Dev (1998) 3.45
Assessing family sharing of diabetes responsibilities. J Pediatr Psychol (1990) 3.43
Mutations that alter the DNA sequence specificity of the catabolite gene activator protein of E. coli. Nature (1984) 3.42
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med (1989) 3.32
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
Random mutagenesis of gene-sized DNA molecules by use of PCR with Taq DNA polymerase. Nucleic Acids Res (1991) 3.18
Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet (1981) 2.95
Domain organization of RNA polymerase alpha subunit: C-terminal 85 amino acids constitute a domain capable of dimerization and DNA binding. Cell (1994) 2.89
Transcription activation at class II CAP-dependent promoters: two interactions between CAP and RNA polymerase. Cell (1996) 2.88
Normal brain in human newborns: apparent diffusion coefficient and diffusion anisotropy measured by using diffusion tensor MR imaging. Radiology (1998) 2.81
Structure of the CAP-DNA complex at 2.5 angstroms resolution: a complete picture of the protein-DNA interface. J Mol Biol (1996) 2.80
DNA-binding determinants of the alpha subunit of RNA polymerase: novel DNA-binding domain architecture. Genes Dev (1996) 2.72
Mechanism of ATP-dependent promoter melting by transcription factor IIH. Science (2000) 2.62
HIV-1 RT-associated ribonuclease H displays both endonuclease and 3'----5' exonuclease activity. EMBO J (1990) 2.54
Reliability of the Washington University Clinical Dementia Rating. Arch Neurol (1988) 2.48
The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation (1984) 2.45
The prevalence and correlates of fear of falling in elderly persons living in the community. Am J Public Health (1994) 2.37
Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology (2000) 2.31
Hyperlipidaemia, hypertension, and coronary heart disease. Lancet (1995) 2.28
Processing protease and reverse transcriptase from human immunodeficiency virus type I polyprotein in Escherichia coli. J Virol (1988) 2.28
Structural organization of the RNA polymerase-promoter open complex. Cell (2000) 2.25
Improved evaluation of the location and mechanism of mitral valve regurgitation with a systematic transesophageal echocardiography examination. Anesth Analg (1999) 2.23
Transcription activation at class II CAP-dependent promoters. Mol Microbiol (1997) 2.22
A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol (1998) 2.22
Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function. FEBS Lett (1989) 2.20
Translocation of sigma(70) with RNA polymerase during transcription: fluorescence resonance energy transfer assay for movement relative to DNA. Cell (2001) 2.17
Bacterial promoter architecture: subsite structure of UP elements and interactions with the carboxy-terminal domain of the RNA polymerase alpha subunit. Genes Dev (1999) 2.13
Production and properties of the alpha core derived from the cyclic adenosine monophosphate receptor protein of Escherichia coli. Biochemistry (1978) 2.13
Identification of the activating region of catabolite gene activator protein (CAP): isolation and characterization of mutants of CAP specifically defective in transcription activation. Proc Natl Acad Sci U S A (1993) 2.08
Site-specific incorporation of fluorescent probes into protein: hexahistidine-tag-mediated fluorescent labeling with (Ni(2+):nitrilotriacetic Acid (n)-fluorochrome conjugates. J Am Chem Soc (2001) 2.08
Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve (1983) 1.99
Cooperative DNA binding of heterologous proteins: evidence for contact between the cyclic AMP receptor protein and RNA polymerase. Proc Natl Acad Sci U S A (1988) 1.94
Molecular basis of DNA sequence recognition by the catabolite gene activator protein: detailed inferences from three mutations that alter DNA sequence specificity. Proc Natl Acad Sci U S A (1984) 1.94
Interaction of HIV-1 reverse transcriptase with a synthetic form of its replication primer, tRNA(Lys,3). Nucleic Acids Res (1991) 1.91
Trajectory of DNA in the RNA polymerase II transcription preinitiation complex. Proc Natl Acad Sci U S A (1997) 1.89
Location, structure, and function of the target of a transcriptional activator protein. Genes Dev (1994) 1.88
DNA sequence determinants for binding of the Escherichia coli catabolite gene activator protein. J Biol Chem (1992) 1.88
The catabolite-sensitive promoter for the chloramphenicol acetyl transferase gene is preceded by two binding sites for the catabolite gene activator protein. J Bacteriol (1982) 1.87
Very Early Constraint-Induced Movement during Stroke Rehabilitation (VECTORS): A single-center RCT. Neurology (2009) 1.87
Characterization of the activating region of Escherichia coli catabolite gene activator protein (CAP). II. Role at Class I and class II CAP-dependent promoters. J Mol Biol (1994) 1.86
Rapid RNA polymerase genetics: one-day, no-column preparation of reconstituted recombinant Escherichia coli RNA polymerase. Proc Natl Acad Sci U S A (1995) 1.85
Broadband neural encoding in the cricket cercal sensory system enhanced by stochastic resonance. Nature (1996) 1.80
The stomatogastric nervous system: structure and function of a small neural network. Prog Neurobiol (1976) 1.80
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci (1977) 1.79
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol (1991) 1.78
High-resolution mapping of nucleoprotein complexes by site-specific protein-DNA photocrosslinking: organization of the human TBP-TFIIA-TFIIB-DNA quaternary complex. Proc Natl Acad Sci U S A (1996) 1.78
Identification of the target of a transcription activator protein by protein-protein photocrosslinking. Science (1994) 1.77
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Bacterial RNA polymerase subunit omega and eukaryotic RNA polymerase subunit RPB6 are sequence, structural, and functional homologs and promote RNA polymerase assembly. Proc Natl Acad Sci U S A (2001) 1.76
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology (1993) 1.75
Pretreatment blood pressure as a predictor of 21-year mortality. Am J Hypertens (2000) 1.75
Role of glutamic acid-181 in DNA-sequence recognition by the catabolite gene activator protein (CAP) of Escherichia coli: altered DNA-sequence-recognition properties of [Val181]CAP and [Leu181]CAP. Proc Natl Acad Sci U S A (1987) 1.75
A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med (2001) 1.74
Transcription activation at Class II CRP-dependent promoters: identification of determinants in the C-terminal domain of the RNA polymerase alpha subunit. EMBO J (1998) 1.73
Fluorescence anisotropy: rapid, quantitative assay for protein-DNA and protein-protein interaction. Methods Enzymol (1996) 1.72
Interlaboratory histopathologic assessment of Alzheimer neuropathology: different methodologies yield comparable diagnostic results. Alzheimer Dis Assoc Disord (1993) 1.72
The functional subunit of a dimeric transcription activator protein depends on promoter architecture. EMBO J (1994) 1.70
Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther (1992) 1.67
Rapid killing of single neurons by irradiation of intracellularly injected dye. Science (1979) 1.67
Cyclic adenosine monophosphate receptor: loss of cAMP-dependent DNA binding activity after proteolysis in the presence of cyclic adenosine monophosphate. Proc Natl Acad Sci U S A (1973) 1.67
Temporal encoding in nervous systems: a rigorous definition. J Comput Neurosci (1995) 1.67
RNA polymerase beta' subunit: a target of DNA binding-independent activation. Science (1997) 1.63
Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? Br Med J (Clin Res Ed) (1986) 1.60
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. Pediatrics (1998) 1.60
Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion (2001) 1.60
Alzheimer disease and cancer. Neurology (2005) 1.60
Evidence for a contact between glutamine-18 of lac repressor and base pair 7 of lac operator. Proc Natl Acad Sci U S A (1986) 1.59
Structural basis for the specificity of the initiation of HIV-1 reverse transcription. EMBO J (1999) 1.59
Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension (1995) 1.58
The transient respiratory effects in man of sudden changes in alveolar CO2 in hypoxia and in high oxygen. Respir Physiol (1974) 1.58
A combined hospital experience with fundoplication and gastric emptying procedure for gastroesophageal reflux in children. J Am Coll Surg (1995) 1.57
Antacid maintenance therapy in the prevention of duodenal ulcer relapse. Gut (1988) 1.54
Chronic progressive renal disease: rate of change of serum creatinine concentration. Kidney Int (1977) 1.52
Protein-protein interactions in eukaryotic transcription initiation: structure of the preinitiation complex. Proc Natl Acad Sci U S A (1996) 1.50
Characterization of the activating region of Escherichia coli catabolite gene activator protein (CAP). I. Saturation and alanine-scanning mutagenesis. J Mol Biol (1994) 1.50
Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol (1988) 1.48
A controlled clinical trial of local anesthesia for lumbar punctures in newborns. Pediatrics (1991) 1.47
Falls in the elderly: reliability of a classification system. J Am Geriatr Soc (1991) 1.46
Identification of the functional subunit of a dimeric transcription activator protein by use of oriented heterodimers. Cell (1993) 1.46
A comparison of two computer-administered versions of the NIMH Diagnostic Interview Schedule. J Psychiatr Res (1992) 1.45
Expression of biologically active human T-cell lymphotropic virus type III reverse transcriptase in Bacillus subtilis. Gene (1987) 1.43
The differential ferrioxamine test in the management of idiopathic haemochromatosis. Lancet (1969) 1.43
Family characteristics of diabetic adolescents: relationship to metabolic control. Diabetes Care (1982) 1.43
Use of a modified shell vial technique to quantitate cytomegalovirus viremia in a population of solid-organ transplant recipients. J Clin Microbiol (1992) 1.43
Two-dimensional crystallization of histidine-tagged, HIV-1 reverse transcriptase promoted by a novel nickel-chelating lipid. J Struct Biol (1995) 1.41